{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T03:15:31Z","timestamp":1790306131217,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019717","name":"AstraZeneca Pharmaceutical Spain","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019717","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","resmedjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Medicine"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.rmed.2025.107940","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T16:39:11Z","timestamp":1736786351000},"page":"107940","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["The impact of blood eosinophil count and FeNO on benralizumab effectiveness in clinical practice: An ORBE II subanalysis"],"prefix":"10.1016","volume":"237","author":[{"given":"Ismael","family":"Garc\u00eda-Moguel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Mart\u00ednez-Mesa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6714-9438","authenticated-orcid":false,"given":"Rub\u00e9n","family":"And\u00fajar-Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roc\u00edo","family":"D\u00edaz-Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luis","family":"Velasco-Garrido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9150-1315","authenticated-orcid":false,"given":"Jose Luis","family":"Sanchez-Trincado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Luzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9365-6361","authenticated-orcid":false,"given":"Javier","family":"Nuevo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Alconada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel","family":"Niza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicia","family":"Padilla-Galo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.rmed.2025.107940_bib1","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.chest.2021.04.013","article-title":"Eosinophilic and noneosinophilic asthma: an expert consensus framework to characterize phenotypes in a global real-life severe asthma cohort","volume":"160","author":"Heaney","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.rmed.2025.107940_bib2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.rmed.2019.03.006","article-title":"Unmet therapeutic goals and potential treatable traits in a population of patients with severe uncontrolled asthma in Spain. ENEAS study","volume":"151","author":"P\u00e9rez de Llano","year":"2019","journal-title":"Respir. Med."},{"issue":"7","key":"10.1016\/j.rmed.2025.107940_bib3","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S2213-2600(23)00230-8","article-title":"GINA report for asthma","volume":"11","author":"Venkatesan","year":"2023","journal-title":"Lancet Respir. Med."},{"issue":"9","key":"10.1016\/j.rmed.2025.107940_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10092181","article-title":"Eosinophilic inflammation: an appealing target for pharmacologic treatments in severe asthma","volume":"10","author":"Vatrella","year":"2022","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.rmed.2025.107940_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.opresp.2023.100277","article-title":"GEMA 5.3. Spanish guideline on the management of asthma","volume":"5","author":"Plaza Moral","year":"2023","journal-title":"Open Respiratory Archives"},{"issue":"2","key":"10.1016\/j.rmed.2025.107940_bib6","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jaci.2021.11.021","article-title":"Considering biomarkers in asthma disease severity","volume":"149","author":"Custovic","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"issue":"12","key":"10.1016\/j.rmed.2025.107940_bib7","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1111\/all.13628","article-title":"Recent developments and highlights in biomarkers in allergic diseases and asthma","volume":"73","author":"Eguiluz-Gracia","year":"2018","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.rmed.2025.107940_bib8","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.anai.2014.04.011","article-title":"High blood eosinophil count is associated with more frequent asthma attacks in asthma patients","volume":"113","author":"Tran","year":"2014","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"11","key":"10.1016\/j.rmed.2025.107940_bib9","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","article-title":"Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study","volume":"3","author":"Price","year":"2015","journal-title":"Lancet Respir. Med."},{"issue":"4","key":"10.1016\/j.rmed.2025.107940_bib10","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02536-2017","article-title":"Associations between blood eosinophils and decline in lung function among adults with and without asthma","volume":"51","author":"Hancox","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"7","key":"10.1016\/j.rmed.2025.107940_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0201143","article-title":"Association between blood eosinophil count and risk of readmission for patients with asthma: historical cohort study","volume":"13","author":"Kerkhof","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.rmed.2025.107940_bib12","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.rmed.2018.08.005","article-title":"Disconnect of type 2 biomarkers in severe asthma; dominated by FeNO as a predictor of exacerbations and periostin as predictor of reduced lung function","volume":"143","author":"Mansur","year":"2018","journal-title":"Respir. Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.107940_bib13","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jaip.2016.08.002","article-title":"Determinants of incomplete asthma control in patients with allergic rhinitis and asthma","volume":"5","author":"Oka","year":"2017","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"10.1016\/j.rmed.2025.107940_bib14","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13601-019-0282-7","article-title":"Association of elevated fractional exhaled nitric oxide concentration and blood eosinophil count with severe asthma exacerbations","volume":"9","author":"Price","year":"2019","journal-title":"Clin. Transl. Allergy"},{"key":"10.1016\/j.rmed.2025.107940_bib15","article-title":"[Consensus document for severe asthma in adults. 2022 update]","volume":"4","author":"Alvarez-Guti\u00e9rrez","year":"2022","journal-title":"Open respiratory archives"},{"issue":"5","key":"10.1016\/j.rmed.2025.107940_bib16","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1164\/rccm.9120-11ST","article-title":"An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications","volume":"184","author":"Dweik","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"1","key":"10.1016\/j.rmed.2025.107940_bib17","first-page":"36","article-title":"Fractional exhaled nitric oxide (FENO) in the management of asthma: a position paper of the Italian respiratory society (SIP\/IRS) and Italian society of allergy, asthma and clinical immunology (SIAAIC)","volume":"15","author":"Heffler","year":"2020","journal-title":"Multidiscip Respir Med"},{"issue":"8","key":"10.1016\/j.rmed.2025.107940_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics13081428","article-title":"Update on the role of FeNO in asthma management","volume":"13","author":"Murugesan","year":"2023","journal-title":"Diagnostics"},{"key":"10.1016\/j.rmed.2025.107940_bib19","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2466-13-11","article-title":"Distribution of sputum cellular phenotype in a large asthma cohort: predicting factors for eosinophilic vs neutrophilic inflammation","volume":"13","author":"Schleich","year":"2013","journal-title":"BMC Pulm. Med."},{"issue":"2","key":"10.1016\/j.rmed.2025.107940_bib20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1136\/thoraxjnl-2014-205634","article-title":"External validation of blood eosinophils, FE(NO) and serum periostin as surrogates for sputum eosinophils in asthma","volume":"70","author":"Wagener","year":"2015","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.rmed.2025.107940_bib21","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.jaip.2021.10.059","article-title":"Effective management of severe asthma with biologic medications in adult patients: a literature review and international expert opinion","volume":"10","author":"Buhl","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"7","key":"10.1016\/j.rmed.2025.107940_bib22","doi-asserted-by":"crossref","first-page":"2680","DOI":"10.1016\/j.jaip.2021.02.059","article-title":"Cluster analysis of inflammatory biomarker expression in the international severe asthma registry","volume":"9","author":"Denton","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"10","key":"10.1016\/j.rmed.2025.107940_bib23","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/S2213-2600(21)00124-7","article-title":"Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis","volume":"9","author":"Busse","year":"2021","journal-title":"Lancet Respir. Med."},{"issue":"10056","key":"10.1016\/j.rmed.2025.107940_bib24","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta(2)-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"issue":"10056","key":"10.1016\/j.rmed.2025.107940_bib25","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.rmed.2025.107940_bib26","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.rmed.2025.107940_bib27","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-world effectiveness of benralizumab in severe eosinophilic asthma","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.rmed.2025.107940_bib28","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/s12931-022-01952-8","article-title":"ChAracterization of Italian severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study","volume":"23","author":"Menzella","year":"2022","journal-title":"Respir. Res."},{"issue":"1","key":"10.1016\/j.rmed.2025.107940_bib29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.18176\/jiaci.0599","article-title":"Benralizumab in real life","volume":"31","author":"Miralles Lopez","year":"2021","journal-title":"J Investig. Allergol. Clin. Immunol."},{"key":"10.1016\/j.rmed.2025.107940_bib30","doi-asserted-by":"crossref","first-page":"163","DOI":"10.15586\/aei.v50i6.704","article-title":"Analysis of response of severe eosinophilic asthmatic patients to benralizumab","volume":"50","author":"L\u00f3pez","year":"2022","journal-title":"Allergol. Immunopathol."},{"key":"10.1016\/j.rmed.2025.107940_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110444","article-title":"Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma","volume":"129","author":"Pelaia","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.rmed.2025.107940_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2019.101830","article-title":"Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose","volume":"58","author":"Pelaia","year":"2019","journal-title":"Pulm. Pharmacol. Ther."},{"issue":"20","key":"10.1016\/j.rmed.2025.107940_bib33","first-page":"7461","article-title":"Severe asthma and long-term Benralizumab effectiveness in real-life","volume":"26","author":"Sposato","year":"2022","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"1","key":"10.1016\/j.rmed.2025.107940_bib34","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12931-023-02539-7","article-title":"Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study","volume":"24","author":"Padilla-Galo","year":"2023","journal-title":"Respir. Res."},{"issue":"9","key":"10.1016\/j.rmed.2025.107940_bib35","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1080\/03007995.2017.1347091","article-title":"The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies","volume":"33","author":"Goldman","year":"2017","journal-title":"Curr. Med. Res. Opin."},{"issue":"4","key":"10.1016\/j.rmed.2025.107940_bib36","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00936-2018","article-title":"Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma","volume":"52","author":"Bleecker","year":"2018","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.rmed.2025.107940_bib37","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jaci.2018.08.031","article-title":"Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: indirect treatment comparison","volume":"143","author":"Busse","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.rmed.2025.107940_bib38","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir. Med."},{"issue":"6","key":"10.1016\/j.rmed.2025.107940_bib39","doi-asserted-by":"crossref","first-page":"163","DOI":"10.15586\/aei.v50i6.704","article-title":"Analysis of response of severe eosinophilic asthmatic patients to benralizumab","volume":"50","author":"Miralles-Lopez","year":"2022","journal-title":"Allergol. Immunopathol."},{"issue":"6","key":"10.1016\/j.rmed.2025.107940_bib40","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.jaip.2022.02.014","article-title":"Benralizumab effectiveness in severe asthma is independent of previous biologic use","volume":"10","author":"Jackson","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"3","key":"10.1016\/j.rmed.2025.107940_bib41","article-title":"[Consensus document for severe asthma in adults. 2022 update]","volume":"4","author":"Alvarez-Gutierrez","year":"2022","journal-title":"Open Respir Arch"},{"issue":"3","key":"10.1016\/j.rmed.2025.107940_bib42","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jaci.2019.12.006","article-title":"An expert consensus framework for asthma remission as a treatment goal","volume":"145","author":"Menzies-Gow","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"issue":"6","key":"10.1016\/j.rmed.2025.107940_bib43","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.jaip.2023.02.020","article-title":"Clinical implications of longitudinal blood eosinophil counts in patients with severe asthma","volume":"11","author":"Bleecker","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"1","key":"10.1016\/j.rmed.2025.107940_bib44","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1183\/09031936.00201813","article-title":"Importance of concomitant local and systemic eosinophilia in uncontrolled asthma","volume":"44","author":"Schleich","year":"2014","journal-title":"Eur. Respir. J."},{"issue":"4","key":"10.1016\/j.rmed.2025.107940_bib45","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S2213-2600(15)00050-8","article-title":"Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis","volume":"3","author":"Korevaar","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.rmed.2025.107940_bib46","doi-asserted-by":"crossref","DOI":"10.23970\/AHRQEPCCER197","article-title":"The clinical utility of fractional exhaled nitric oxide (FeNO) in asthma management","author":"Wang","year":"2017"},{"issue":"2","key":"10.1016\/j.rmed.2025.107940_bib47","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.anai.2022.02.021","article-title":"Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptions","volume":"129","author":"Oppenheimer","year":"2022","journal-title":"Ann. Allergy Asthma Immunol."},{"issue":"4","key":"10.1016\/j.rmed.2025.107940_bib48","article-title":"GEMA 5.3. Spanish guideline on the management of asthma","volume":"5","author":"Plaza Moral","year":"2023","journal-title":"Open Respir Arch"},{"issue":"4","key":"10.1016\/j.rmed.2025.107940_bib49","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/cea.13790","article-title":"Overlap of allergic, eosinophilic and type 2 inflammatory subtypes in moderate-to-severe asthma","volume":"51","author":"Chen","year":"2021","journal-title":"Clin. Exp. Allergy"},{"issue":"2","key":"10.1016\/j.rmed.2025.107940_bib50","doi-asserted-by":"crossref","first-page":"AB13","DOI":"10.1016\/j.jaci.2022.12.045","article-title":"Asthma clinical remission with benralizumab in an integrated analysis of the real-world XALOC-1 study","volume":"151","author":"Jackson","year":"2023","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2025.107940_bib51","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.631660","article-title":"Effectiveness of benralizumab in improving the quality of life of severe eosinophilic asthmatic patients: our real-life experience","volume":"12","author":"Scioscia","year":"2021","journal-title":"Front. Pharmacol."},{"issue":"3","key":"10.1016\/j.rmed.2025.107940_bib52","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.jaip.2020.10.010","article-title":"Long-Term therapy response to anti-IL-5 biologics in severe asthma-A real-life evaluation","volume":"9","author":"Eger","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"8","key":"10.1016\/j.rmed.2025.107940_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12082900","article-title":"A real-world study of achievement rate and predictive factors of clinical and deep remission to biologics in patients with severe asthma","volume":"12","author":"Oishi","year":"2023","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.rmed.2025.107940_bib54","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.jaci.2015.05.039","article-title":"Blood eosinophil counts predict treatment response in patients with severe eosinophilic asthma","volume":"136","author":"Ortega","year":"2015","journal-title":"J. Allergy Clin. Immunol."},{"issue":"1","key":"10.1016\/j.rmed.2025.107940_bib55","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12931-019-1056-4","article-title":"Oral corticosteroid dose changes and impact on peripheral blood eosinophil counts in patients with severe eosinophilic asthma: a post hoc analysis","volume":"20","author":"Prazma","year":"2019","journal-title":"Respir. Res."},{"issue":"2","key":"10.1016\/j.rmed.2025.107940_bib56","doi-asserted-by":"crossref","first-page":"AB28","DOI":"10.1016\/j.jaci.2019.12.813","article-title":"Inhaled corticosteroid use and its implication in peripheral eosinophil level","volume":"145","author":"Franco","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.rmed.2025.107940_bib57","doi-asserted-by":"crossref","first-page":"605","DOI":"10.2147\/JAA.S270298","article-title":"Switch from IL-5 to IL-5-receptor \u03b1 antibody treatment in severe eosinophilic asthma","volume":"13","author":"Drick","year":"2020","journal-title":"J. Asthma Allergy"},{"issue":"6","key":"10.1016\/j.rmed.2025.107940_bib58","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1111\/all.14693","article-title":"Benralizumab after sub-optimal response to mepolizumab in severe eosinophilic asthma","volume":"76","author":"Kavanagh","year":"2021","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.rmed.2025.107940_bib59","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1186\/s12890-021-01785-z","article-title":"Real-world study in severe eosinophilic asthma patients refractory to anti-IL5 biological agents treated with benralizumab in Spain (ORBE study)","volume":"21","author":"Martinez-Moragon","year":"2021","journal-title":"BMC Pulm. Med."},{"issue":"4","key":"10.1016\/j.rmed.2025.107940_bib60","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.jaci.2018.01.008","article-title":"Benralizumab attenuates airway eosinophilia in prednisone-dependent asthma","volume":"141","author":"Sehmi","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"issue":"4","key":"10.1016\/j.rmed.2025.107940_bib61","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00936-2018","article-title":"Baseline patient factors impact on the clinical efficacy of benralizumab for severe asthma","volume":"52","author":"Bleecker","year":"2018","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.rmed.2025.107940_bib62","doi-asserted-by":"crossref","DOI":"10.1177\/2058738420950851","article-title":"Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma","volume":"34","author":"Lombardo","year":"2020","journal-title":"Int. J. Immunopathol. Pharmacol."},{"issue":"5","key":"10.1016\/j.rmed.2025.107940_bib63","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.jaip.2021.01.008","article-title":"The relationship between Feno and effectiveness of mepolizumab and benralizumab in severe eosinophilic asthma","volume":"9","author":"Hearn","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"3","key":"10.1016\/j.rmed.2025.107940_bib64","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1164\/rccm.200711-1754OC","article-title":"Cluster analysis and clinical asthma phenotypes","volume":"178","author":"Haldar","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.rmed.2025.107940_bib65","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/j.0105-2896.2004.00215.x","article-title":"Interleukin-13 in asthma pathogenesis","volume":"202","author":"Wills-Karp","year":"2004","journal-title":"Immunol. Rev."},{"issue":"2","key":"10.1016\/j.rmed.2025.107940_bib66","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00210-008-0286-7","article-title":"Arginase and pulmonary diseases","volume":"378","author":"Maarsingh","year":"2008","journal-title":"Naunyn-Schmiedeberg\u2019s Arch. Pharmacol."},{"issue":"3","key":"10.1016\/j.rmed.2025.107940_bib67","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1152\/physrev.00034.2003","article-title":"Nitric oxide in health and disease of the respiratory system","volume":"84","author":"Ricciardolo","year":"2004","journal-title":"Physiol. Rev."},{"issue":"4","key":"10.1016\/j.rmed.2025.107940_bib68","doi-asserted-by":"crossref","DOI":"10.1002\/clt2.12143","article-title":"Effects of anti-IL5 biological treatments on blood IgE levels in severe asthmatic patients: a real-life multicentre study (BIONIGE)","volume":"12","author":"Contoli","year":"2022","journal-title":"Clin. Transl. Allergy"}],"container-title":["Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125000022?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0954611125000022?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T19:47:04Z","timestamp":1740426424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0954611125000022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":68,"alternative-id":["S0954611125000022"],"URL":"https:\/\/doi.org\/10.1016\/j.rmed.2025.107940","relation":{},"ISSN":["0954-6111"],"issn-type":[{"value":"0954-6111","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of blood eosinophil count and FeNO on benralizumab effectiveness in clinical practice: An ORBE II subanalysis","name":"articletitle","label":"Article Title"},{"value":"Respiratory Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmed.2025.107940","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107940"}}